Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia has entered binding agreements to acquire four hand therapy clinics in Sydney, NSW
  • The company purchased the hand therapy clinics for $3.5 million
  • The clinics are expected to bring in a revenue of $2.7 million

Healthia has entered binding agreements to acquire four hand therapy clinics in Sydney, NSW.

The company acquired the hand therapy clinics for $3.5 million.

The clinics will be funded by the company utilising the undrawn debt available under the facility agreement with ANZ and BOQ.

Healthia is an integrated group of health based companies whose mission is to enrich lives of people through world-class health services.

The group includes My FootDr, Allsports Physiotherapy, Extend Rehabilitation, iOrthotics and D.B.S. Medical Supplies.

The company is currently Australasia’s (Australia, New Zealand and neighbouring islands) leading allied health group.

CEO of the company’s physiotherapy branch Tony Ganter is happy with the acquisition.

“The four speciality hand therapy clinics, which provide physiotherapy and occupational therapy for the hand and upper limb, complement our existing nine Extend Hand Therapy clinics in Queensland,” he said.

Hand Therapy is evaluating and treating injuries and conditions in the shoulder, arm, elbow, forearm, wrist and hand.

The clinics are expected to bring in a revenue of $2.7 million.

“We are pleased that we are able to expand these speciality services across the group,” Tony said.

Healthia’s share price has increased 2.37 per cent today and is currently selling shares at $1.08 per share.

HLA by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer.

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…